Alnylam Pharmace. buy Saftman
Summary
This prediction ended on 08.07.22 with a price of €149.84. With a performance of 2.31%, the BUY prediction by Saftman for Alnylam Pharmace. closed with a slight gain. Saftman has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | 1.017% | 1.017% | 22.947% | 42.969% |
iShares Core DAX® | -0.598% | 0.645% | 10.813% | 15.396% |
iShares Nasdaq 100 | -3.290% | -4.193% | 23.772% | 40.773% |
iShares Nikkei 225® | -0.796% | -0.582% | 8.390% | 8.288% |
iShares S&P 500 | -1.164% | -0.857% | 23.003% | 41.152% |
Comments by Saftman for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.